Literature DB >> 10946892

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

C Wang1, R S Swerdloff, A Iranmanesh, A Dobs, P J Snyder, G Cunningham, A M Matsumoto, T Weber, N Berman.   

Abstract

Testosterone (T) therapy for hypogonadal men should correct the clinical abnormalities of T deficiency, including improvement of sexual function, increase in muscle mass and strength, and decrease in fat mass, with minimal adverse effects. We have shown that administration of a new transdermal T gel formulation to hypogonadal men provided dose proportional increases in serum T levels to the normal adult male range. We now report the effects of 180 days of treatment with this 1% T gel preparation (50 or 100 mg/day, contained in 5 or 10 g gel, respectively) compared to those of a permeation-enhanced T patch (5 mg/day) on defined efficacy parameters in 227 hypogonadal men. In the T gel groups, the T dose was adjusted up or down to 75 mg/day (contained in 7.5 g gel) on day 90 if serum T concentrations were below or above the normal male range. No dose adjustment was made with the T patch group. Sexual function and mood changes were monitored by questionnaire, body composition was determined by dual energy x-ray absorptiometry, and muscle strength was measured by the one repetitive maximum technique on bench and leg press exercises. Sexual function and mood improved maximally on day 30 of treatment, without differences across groups, and showed no further improvement with continuation of treatment. Mean muscle strength in the leg press exercise increased by 11 to 13 kg in all treatment groups by 90 days and did not improve further at 180 days of treatment. Moderate increases were also observed in arm/chest muscle strength. At 90 days of treatment, lean body mass increased more in the 100 mg/day T gel group (2.74 +/- 0.28 kg; P = 0.0002) than in the 50 mg/day T gel (1.28 +/- 0.32 kg) and T patch groups (1.20 +/- 0.26 kg). Fat mass and percent fat were not significantly decreased in the T patch group, but showed decreases in the T gel groups (50 mg/day, -0.90 +/- 0.32 kg; 100 mg/day, - 1.05 +/- 0.22 kg). The increase in lean mass and the decrease in fat mass were correlated with the changes in average serum T levels attained after transdermal T replacement. These beneficial effects of T replacement were accompanied by the anticipated increases in hematocrit and hemoglobin but without significant changes in the lipid profile. The increase in mean serum prostate-specific antigen levels (within the normal range) was correlated with serum levels of T. The greatest increases were noted in the 100 mg/day T gel group. Skin irritation was reported in 5.5% of subjects treated with T gel and in 66% of subjects in the permeation-enhanced T patch group. We conclude that T gel replacement improved sexual function and mood, increased lean mass and muscle strength (principally in the legs), and decreased fat mass in hypogonadal men with less skin irritation and discontinuation compared with the recommended dose of the permeation-enhanced T patch.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946892     DOI: 10.1210/jcem.85.8.6747

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  149 in total

Review 1.  Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review.

Authors:  Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey
Journal:  J Spinal Cord Med       Date:  2017-08-03       Impact factor: 1.985

Review 2.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 3.  The endocrine pharmacology of testosterone therapy in men.

Authors:  Michael Oettel
Journal:  Naturwissenschaften       Date:  2004-01-28

Review 4.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 5.  Effects of androgen replacement on metabolism and physical performances in male hypogonadism.

Authors:  M Zitzmann; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

6.  Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.

Authors:  Stephen E Borst; Joshua F Yarrow; Christine F Conover; Unyime Nseyo; John R Meuleman; Judyta A Lipinska; Randy W Braith; Darren T Beck; Jeffrey S Martin; Matthew Morrow; Shirley Roessner; Luke A Beggs; Sean C McCoy; Darryl F Cannady; Jonathan J Shuster
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

Review 7.  [Hypogonadism in the elderly man. Reliable diagnosis and therapy].

Authors:  M Zitzmann; E Nieschlag
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

8.  Preliminary evidence that androgen signaling is correlated with men's everyday language.

Authors:  Jennifer S Mascaro; Kelly E Rentscher; Patrick D Hackett; Adriana Lori; Alana Darcher; James K Rilling; Matthias R Mehl
Journal:  Am J Hum Biol       Date:  2018-05-11       Impact factor: 1.937

9.  Serum total testosterone level and identification of late-onset hypogonadism: a community-based study.

Authors:  Sungmin Kang; Hyun Jun Park; Nam Cheol Park
Journal:  Korean J Urol       Date:  2013-09-10

Review 10.  Diagnosing and managing low serum testosterone.

Authors:  Ana Marcella Rivas; Zachary Mulkey; Joaquin Lado-Abeal; Shannon Yarbrough
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.